# Monte Rosa Therapeutics (GLUE) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/GLUE
## Company Profile
- Ticker: GLUE
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
## Stock Data
- Close: 15.71 USD
- Market cap: 1498664875.32 USD
- Last updated: 2026-08-06
## Business Overview
### Molecular Glue Degraders
Monte Rosa Therapeutics develops small-molecule molecular glues that redirect cellular machinery to degrade disease-causing proteins. The platform is intended to address targets that are difficult to inhibit conventionally.
### MRT-8102
MRT-8102 is a NEK7-directed molecular glue degrader being developed for inflammatory and cardiometabolic diseases. Clinical work includes cardiovascular-risk, gout and hidradenitis-suppurativa populations.
### MRT-2359 and Oncology Pipeline
MRT-2359 targets GSPT1 and is being evaluated with androgen-receptor inhibitors in metastatic castration-resistant prostate cancer.
### Cyclin E1 Program
Monte Rosa is preparing a selective cyclin E1-directed molecular glue degrader for clinical development in tumors driven by cyclin E dysregulation.
## Why The Stock Is Moving

The latest company update was “Monte Rosa Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates”. GLUE changed 0.64% and closed at $15.71 on Aug 6, 2026, indicating a relatively limited closing-price reaction to this earnings update.

## Future Catalysts

- Initiation of a Phase 2 cardiovascular-risk study of MRT-8102 in the second half of 2026.
- Expanded GFORCE-1 data for MRT-8102 in the second half of 2026.
- Initiation of a Phase 2 study of MRT-2359 plus apalutamide in the third quarter of 2026.
- IND submission for the cyclin E1 degrader in the second half of 2026.
- Initiation of MRT-8102 Phase 2 studies in gout in the fourth quarter of 2026 or first quarter of 2027 and in hidradenitis suppurativa in the first half of 2027.

## Recent News
- 2026-08-06 11:00 EST — [Monte Rosa Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates](https://biopharmsignal.com/news/GLUE/monte-rosa-therapeutics-announces-second-quarter-2026-financial-results-and-busi-1240d177) — Source: Monte Rosa Therapeutics
- 2026-07-02 20:01 EST — [Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/GLUE/monte-rosa-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bc49cd8f) — Source: Monte Rosa Therapeutics
- 2026-05-20 11:00 EST — [Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences](https://biopharmsignal.com/news/GLUE/monte-rosa-therapeutics-to-participate-in-upcoming-investor-conferences-620dbf2c) — Source: Monte Rosa Therapeutics
- 2026-05-07 11:00 EST — [Monte Rosa Therapeutics Announces First Quarter 2026 Financial Results and Business Updates](https://biopharmsignal.com/news/GLUE/monte-rosa-therapeutics-announces-first-quarter-2026-financial-results-and-busin-705bfd4d) — Source: Monte Rosa Therapeutics
- 2026-04-20 11:00 EST — [Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2026 on the Potential of its Cyclin E1 (CCNE1)-directed Molecular Glue Degrader to Treat CCNE1-amplified Solid Tumors](https://biopharmsignal.com/news/GLUE/monte-rosa-therapeutics-presents-preclinical-data-at-american-association-for-ca-19a93152) — Source: Monte Rosa Therapeutics